ISIN | LU0767968745 |
---|---|
Valor Number | |
Bloomberg Global ID | |
Fund Name | Bellevue Obesity Solutions I GBP |
Fund Provider |
Bellevue Asset Management AG
Zürich, Switzerland Phone: +41 44 267 67 00 E-Mail: info@bellevue.ch Web: www.bellevue.ch |
Fund Provider | Bellevue Asset Management AG |
Representative in Switzerland |
Waystone Fund Services (Switzerland) SA Lausanne Phone: 0041213111781 |
Distributor(s) |
Bank am Bellevue AG Küsnacht Phone: +41 44 267 67 67 |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | The investment objective of the fund is to achieve long-term capital growth by investing at least two thirds of the net assets in a portfolio of carefully chosen shares and preference shares of companies whose business is directed towards the prevention and treatment of overweight or obesity and their secondary conditions or companies whose main activity involves holding investments in such companies or financing such companies and that have their registered office or carry out the majority of their economic activity in recognised countries. |
Peculiarities |
Current Price * | 445.22 GBP | 02.04.2025 |
---|---|---|
Previous Price * | 445.25 GBP | 01.04.2025 |
52 Week High * | 508.46 GBP | 30.08.2024 |
52 Week Low * | 445.22 GBP | 02.04.2025 |
NAV * | 445.22 GBP | 02.04.2025 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 27,275,010 | |
Unit/Share Assets *** | ||
Trading Information SIX |
YTD Performance | -1.98% |
31.12.2024 - 02.04.2025
31.12.2024 02.04.2025 |
---|---|---|
YTD Performance (in CHF) | -1.03% |
31.12.2024 - 02.04.2025
31.12.2024 02.04.2025 |
1 month | -7.19% |
03.03.2025 - 02.04.2025
03.03.2025 02.04.2025 |
3 months | -3.34% |
02.01.2025 - 02.04.2025
02.01.2025 02.04.2025 |
6 months | -7.48% |
02.10.2024 - 02.04.2025
02.10.2024 02.04.2025 |
1 year | -6.80% |
02.04.2024 - 02.04.2025
02.04.2024 02.04.2025 |
2 years | -9.49% |
03.04.2023 - 02.04.2025
03.04.2023 02.04.2025 |
3 years | -11.13% |
04.04.2022 - 02.04.2025
04.04.2022 02.04.2025 |
5 years | -15.07% |
15.06.2021 - 02.04.2025
15.06.2021 02.04.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Eli Lilly and Co | 9.94% | |
---|---|---|
UnitedHealth Group Inc | 6.94% | |
Johnson & Johnson | 5.92% | |
AbbVie Inc | 5.68% | |
Novo Nordisk AS Class B | 4.34% | |
Intuitive Surgical Inc | 3.84% | |
AstraZeneca PLC ADR | 3.59% | |
Roche Holding AG | 3.53% | |
Abbott Laboratories | 3.51% | |
Thermo Fisher Scientific Inc | 3.47% | |
Last data update | 28.02.2025 |
TER | 1.57% |
---|---|
TER date | 29.01.2021 |
Performance Fee *** | 0.00% |
PTR | |
Max. Management Fee *** | 0.90% |
Ongoing Charges *** | 1.47% |
SRRI ***
|
|
SRRI date *** | 31.03.2025 |